Medical Breakthrough: Low-Cost Antidepressant Found to Combat Long COVID Fatigue

A Major Advance in Long COVID Treatment

A global research team co-led by McMaster University has announced a significant breakthrough in the treatment of long COVID, identifying one of the first medications proven to meaningfully reduce persistent fatigue. According to a randomized, placebo-controlled clinical trial published in the Annals of Internal Medicine, the widely available antidepressant fluvoxamine significantly improved both energy levels and the overall quality of life for patients struggling with the long-term effects of the virus.

Fatigue remains the most debilitating symptom for the estimated 65 million people living with long COVID worldwide. For many, the exhaustion is so profound that it prevents them from returning to work or engaging in daily family activities. Despite the scale of the crisis, medical guidelines have largely been limited to supportive care and pacing due to a lack of evidence-based pharmacological options.

The REVIVE-TOGETHER Trial Results

The study, known as the REVIVE-TOGETHER trial, involved 399 adults in Brazil who had experienced persistent fatigue for at least 90 days following a COVID-19 infection. Participants were randomly assigned to receive either fluvoxamine, the diabetes medication metformin, or a placebo for 60 days. The results were stark: researchers found a 99 percent probability that fluvoxamine outperformed the placebo in reducing fatigue. Conversely, while metformin has previously shown promise in preventing long COVID if taken during the initial infection, it offered no meaningful benefit for those with established fatigue symptoms.

“This is an important step forward for patients who have been desperate for evidence-based options,” said Edward Mills, senior author and professor at McMaster University. He noted that because fluvoxamine is already widely used and well-understood by the medical community, it has immediate potential for clinical application.

Innovation in Clinical Research

Beyond the discovery of the drug’s efficacy, the trial was notable for its sophisticated Bayesian adaptive design. This allowed the international team—comprising researchers from Stanford, UBC, Duke, and several Brazilian institutions—to reach conclusions more efficiently than traditional trials. The study was able to stop specific treatment arms once the evidence became clear, accelerating the delivery of much-needed data to the public.

While experts emphasize that long COVID is a complex condition that may require multiple treatment pathways, the identification of fluvoxamine provides clinicians with the first strong evidence for a medication that targets the condition’s most common symptom. Further research is expected to determine which specific patient profiles benefit most from the treatment.